736 related articles for article (PubMed ID: 29607968)
1. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
Kurinami N; Sugiyama S; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouch K; Jinnouchi T; Jinnouchi H
Diabetes Res Clin Pract; 2018 Aug; 142():254-263. PubMed ID: 29859912
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Shigiyama F; Kumashiro N; Miyagi M; Ikehara K; Kanda E; Uchino H; Hirose T
Cardiovasc Diabetol; 2017 Jul; 16(1):84. PubMed ID: 28683796
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Fioretto P; Giaccari A; Sesti G
Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
[TBL] [Abstract][Full Text] [Related]
5. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Kato K; Suzuki K; Aoki C; Sagara M; Niitani T; Wakamatsu S; Yanagi K; Aso Y
Expert Opin Pharmacother; 2017 Jun; 18(8):743-751. PubMed ID: 28426260
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Atheroscler Thromb; 2018 Jun; 25(6):467-476. PubMed ID: 29225209
[TBL] [Abstract][Full Text] [Related]
7. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
8. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
[TBL] [Abstract][Full Text] [Related]
15. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
16. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
[TBL] [Abstract][Full Text] [Related]
17. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Sposito AC; Breder I; Soares AAS; Kimura-Medorima ST; Munhoz DB; Cintra RMR; Bonilha I; Oliveira DC; Breder JC; Cavalcante P; Moreira C; Moura FA; de Lima-Junior JC; do Carmo HRP; Barreto J; Nadruz W; Carvalho LSF; Quinaglia T;
Cardiovasc Diabetol; 2021 Mar; 20(1):74. PubMed ID: 33771149
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.
Tosaki T; Kamiya H; Himeno T; Kato Y; Kondo M; Toyota K; Nishida T; Shiroma M; Tsubonaka K; Asai H; Moribe M; Nakaya Y; Nakamura J
Intern Med; 2017; 56(6):597-604. PubMed ID: 28321056
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]